Clinical Trials Logo

Recurrent Mantle Cell Lymphoma clinical trials

View clinical trials related to Recurrent Mantle Cell Lymphoma.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT04939272 Suspended - Clinical trials for Recurrent Mantle Cell Lymphoma

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Start date: June 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects, best dose, and effectiveness of copanlisib and venetoclax in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Copanlisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving copanlisib and venetoclax may help treat patients with mantle cell lymphoma.